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effectiveness plane. The observed proportion of cost and effec-
tiveness pairs were compared by a chi-square as would be gen-
erated for a 2 × 2 table. CONCLUSIONS: The cost-effectiveness
plane can be considered a 2 × 2 table of expected and observed
proportions and a chi-square statistic with one degree of freedom
calculated to assess statistical difference of a bootstrapped dis-
tribution from an expected distribution if the data were gener-
ated by chance.
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OBJECTIVES: The use of lipids, lipoproteins, apolipoproteins
and high sensitive CRP (hs-CRP) in coronary artery disease
(CAD) diagnosis has been widely established, although cost-
effectiveness of these laboratory tests is not completely estab-
lished. METHODS: We constructed 4 models (models with low,
middle, high and very high risk for CAD, according to ATP III
recommendation). The diagnostic capabilities of laboratory test
combinations differs in terms of included markers: total choles-
terol (TC), triglycerides (TG), HDL-c, LDL-c, apolipoproteins B
and A-I (apo B and apo A-I), lipoprotein (a) (Lp(a)), apo(a) iso-
forms and hs-CRP for establishing risk of CAD. The effective-
ness of the laboratory test combinations, in number needed to
diagnose (NND), was established on the random sample of 221
CAD patients who were undergoing coronary angiography and
297 healthy subjects with no history of CAD. The direct medical
costs include price of test reagents and consumables speciﬁc to
each test, disposables need for specimen collection and sample
analysis, equipment amortization, and personal cost for labora-
tory technologist. ICER and two-way sensitivity analyses were
also calculated and applied. RESULTS: The cost per additional
successfully diagnosed patient for TC, HDL-c and LDL-c labo-
ratory test combination, were 2.4 and 35.4 euro (respectively),
lower than the cost of the TC, HDL-c, apoB in low and TC,
HDL-c, hs-CRP in very high risk groups. In high risk group, TC,
HDL-h, LDL-h had effectiveness 15% (100/NND) lower than
TC, HDL-c, hs-CRP, but overall saving was 11.9 euro. In middle
risk group TC, LDL-c, apo A-I was chosen as the best alterna-
tive. Such laboratory tests combination had effectiveness 17%
lower then TC, LDL-h and hs-CRP, but savings was 6.2 euro.
CONCLUSION: The cost-effectiveness analysis of different
diagnostic test combinations allows better selection of risky
patients at low cost for the society.
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OBJECTIVES: SHAPE is a lifetime Markov model with monthly
cycles that predicts long-term diabetes, cardiovascular disease
and mortality upon treatment with rimonabant of overweight or
obese subjects. It uses Framingham and UKPDS equations. The
objective of this study was to derive cost estimates for the model
outcomes. METHODS: Acute event costs were incorporated
based on routine activity in Cardiff and the Vale during 1999
using data on all inpatient episodes with details of diagnosis and
discharge utilised using HRGs (Health Research Groups). Post-
acute care costs were restricted to oral therapy for prevention of
secondary events using a rules-based approach from current UK
best-practice guidelines assuming optimal care with prescription
costs calculated from the net ingredient cost of drugs speciﬁed
in Part VIII—Basic Prices of Drugs of the NHS Electronic Drug
Tariff. RESULTS: Similar event related mean costs for fatal and
non fatal myocardial infarctions (MI) were calculated (≤1354
versus ≤1377 respectively) and fatal and non-fatal stroke (≤2622
and ≤2514 respectively). Mean events costs associated with
angina were estimated at ≤1183 and for TIA ≤952. The range of
costs was substantial with minimum and maximum MI costs of
≤591 and ≤7025 respectively and for stroke ≤239 and ≤7902
respectively. Events costs associated with angina ranged from
≤320 to ≤8613 and for TIA ranged from ≤610 to ≤4689. The
annual oral therapy management costs for long term chronic
conditions were calculated at ≤158.11 for MI; ≤88.43 for angina;
≤254.45 for stroke; ≤241.68 for TIA and ≤380.39 for diabetes.
CONCLUSION: Deriving HRG-based costs on routine activity
data enabled differential costs for fatal and non fatal events to
be estimated. The costs match typical clinical endpoints in
models using Framingham or UKPDS risk equations.
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OBJECTIVES: Coronary heart disease, stroke and diabetes mel-
litus are among the leading causes of death in Germany and
determine increasing costs for the health care system. Obesity,
hypertension and dyslipidemia are known to increase the disease-
speciﬁc risk of morbidity and mortality. For assessing the cost-
effectiveness of treatment regimes for patients with obesity and
additional cardiometabolic risk factors adequate costing is essen-
tial. A methodological approach was developed to create a data-
base that decision analysts can use for various treatment options
(German Cardiometabolic Cost Database). METHODS: Direct
medical costs were considered for different treatment options
and for costs of the risk factors obesity, hypertension and dys-
lipidemia, of diabetes mellitus type 2 including its micro- and
macrovascular complications, and of the cardiovascular events
coronary heart disease, myocardial infarction and stroke. Field
and desk research was done to obtain data concerning resource
utilisation and was reviewed by clinical experts. Prices have been
taken of ofﬁcial catalogues. Resource utilisation and prices have
been related in a cost database that enables to provide cost data
for different treatment options and for diabetes mellitus type 2,
coronary heart disease, myocardial infarction and stroke.
RESULTS: The German Cardiometabolic Cost Database
includes information of resource utilisation, prices and costs. It
is constructed in a way that supports analyses from different per-
spectives and for different treatment regimes. CONCLUSIONS:
The developed database enables the adaptation of cost data for
future projects due to innovations in treatment of cardiometa-
bolic risk factors.
